Pre-rolled joints are projected to surpass loose flower by 2025 to become the largest category of cannabis products in Canada, now accounting for 34% of the market. This trend demonstrates that consumers are increasingly turning to formats that are convenient, accessible, and easy to carry.

Our member and board director, Philippe Depault of Québec Craft Cannabis, gave an interview to Radio-Canada in which he spoke about the major challenges that cannabis businesses in Canada still face. As he points out: “On the street, within families, people have come to understand that it’s now legal. The biggest stigma really lies on the business side.”

For one day, women from the worlds of agriculture, herbalism, hemp, cannabis, and the living world came together to exchange ideas, learn, build connections, and shine a light on their journeys.

Health Canada is launching a consultation on amendments to the Industrial Hemp Regulations (IHR), with the aim of reducing regulatory requirements and the administrative burden on the sector. Businesses have until June 30 to respond to the survey.

Bringing together more than 130 leaders, the AQIC’s annual general meeting highlighted the economic importance of hemp and cannabis for Quebec, the many initiatives currently underway to structure the industry, and the strategic potential of hemp for regional development and the ecological transition. 

In an industry where compliance, safety, and consistency are essential, companies in the hemp and cannabis sector need to be able to rely on trustworthy partners who can support them at every stage of their growth. With this in mind, we’re pleased to introduce STERIS, a member of AQIC, through an interview with David Terranova, Senior Director of Plant Operations.

L’administration américaine a annoncé la reclassification du cannabis médical vers une catégorie fédérale moins restrictive, le faisant passer de l’annexe I — aux côtés de substances comme l’héroïne — à l’annexe III, où l’on retrouve notamment des médicaments comme le Tylenol avec codéine. Cette décision marque un tournant majeur pour l’industrie. Elle ouvre la voie à un allègement fiscal pour les producteurs autorisés et pourrait également favoriser l’avancement de la recherche.

Since legalization, cannabis use has declined among teenagers. In 2025, 19% of young people aged 15 to 20 reported having used cannabis, compared to 28% in 2018. Conversely, use has increased slightly among adults aged 35 and older, contributing to the rise in the overall percentage of Quebecers who report using cannabis: 17% in 2025, compared to 14% in 2018.

Canadian cannabis producer Organigram Global has acquired Germany’s cannabis company Sanity Group to expand its European presence into regulated cannabis markets.

In Quebec, fewer and fewer young people are using psychoactive substances such as tobacco, alcohol, or cannabis. One exception is e-cigarettes, whose popularity has increased significantly over the past ten years.

A new Canada-wide scientific assessment has found that alcohol causes more harm overall than any other drug in the country—ranking far above tobacco, opioids, cocaine, methamphetamine and cannabis.

According to a new study conducted by researchers at the Hebrew University of Jerusalem, CBD and CBG may help improve liver function and reduce certain markers associated with non-alcoholic fatty liver disease, commonly known as fatty liver disease. This condition is estimated to affect about one in three adults worldwide. This represents a promising breakthrough, not only for cannabinoid research but also for public health.